Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKW22
- Development stage
- Preclinical
- Lead developer
- ARK
- Modality
- Stem Cell Therapies → Cell Therapies, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
CKW22 is a preclinical-stage therapeutic consisting of stem cell-derived exosomes loaded with Transforming Growth Factor Beta 3 (TGF-β3) protein. Developed by Prostemics in partnership with CK-Exogene, it is designed for wound treatment. TGF-β3 is known for its role in scarless wound healing and regulating the inflammatory response. By using exosomes as a delivery vehicle, the therapy aims to enhance the regenerative potential of TGF-β3 while leveraging the innate bioactivity of stem cell-derived extracellular vesicles. The exosome platform provides a stable environment for the protein cargo and facilitates its delivery to target cells at the wound site, promoting tissue regeneration and minimizing fibrosis.
- Other names
- TGF-β3-loaded stem cell exosomeProstemics wound healing exosome
Beyond the preview
Go deeper on CKW22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKW22.